Liver disease Archives

More News! 18 Sep 2019

€15M to Take Swiss Biotech’s Liver Cirrhosis Treatment to Phase II

Versantis has raised a Series B of €14.6M (CHF 16M) to advance its treatment for late-stage liver cirrhosis to a phase IIa trial. The money will finance the completion of an ongoing phase I trial of Versantis’ lead candidate for the condition decompensated liver cirrhosis. Following this, the company will use the funds to launch […]

September 18, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 2 May 2019

Drug for Autoimmune Liver Disease Yields Mixed Results in Hard-to-Treat Patients

Developed by the French biotech Genkyotex, a first-in-class treatment for the liver disease primary biliary cholangitis failed to reduce a key disease biomarker in a phase II trial, but showed potential for reducing liver scarring. Primary biliary cholangitis is an autoimmune disease that damages the liver and can lead to liver scarring (fibrosis) or the […]

May 2, 2019 - 2 minutesmins - By Jonathan Smith

liver fibrosis alentis switzerland cirrhosis cancer

News and Trends 30 Apr 2019

Swiss Biotech Raises €11M to Develop Treatments for Liver Fibrosis

Founded in March this year, Alentis Therapeutics has bagged a Series A round of €11.1M (CHF 12.5M) to develop antibody drugs treating liver fibrosis, which currently has no approved treatments. Liver fibrosis is the scarring of liver tissue, which can happen as a consequence of aging, chronic hepatitis or conditions such as non-alcoholic steatohepatitis (NASH). […]

April 30, 2019 - 2 minutesmins - By Jonathan Smith

promethera liver failure stem cell therapy

News and Trends 15 Apr 2019

First Stem Cell Therapy for Liver Failure Shows Promise in First Human Trials

A stem cell therapy developed by the Belgian company Promethera has improved symptoms, such as jaundice, in patients with acute liver failure, a condition with no effective treatments. A phase I/IIa trial of the therapy recruited 19 patients with chronic liver disease. Of these,12 patients had developed acute-on-chronic liver failure, a life-threatening syndrome where the […]

April 15, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 27 Mar 2019

Genfit Gets Ready to Launch Drug for Untreated Liver Disease Raising €120M

After some big failures from its top competitors earlier this year, French company Genfit has done an IPO to prepare the launch of its drug for NASH, a chronic liver disease for which there is currently no treatment. Today, Genfit has started trading on Nasdaq. Together with issuing new shares in its existing Euronext Paris […]

March 27, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

autoimmune liver disease Genkyotex organ

News and Trends 7 Nov 2018

Solid Phase II Performance for French Autoimmune Liver Disease Drug

Genkyotex’s small molecule therapy had encouraging short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial. Over six weeks, the drug reduced the blood levels of a liver disease biomarker molecule by up to 23% in 92 participants. In patients with late-stage disease, who have few treatments available, […]

November 7, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 20 Sep 2018

RNA Therapy Shows Promise for Treating Liver Cancer

British biotech MiNA Therapeutics’ innovative RNA treatment may enhance liver cancer patients’ response to standard cancer therapies, suggest early results from a Phase I/IIa clinical trial. When they received the biotech’s small activating RNA (saRNA) treatment, two patients showed complete responses after being given the cancer treatment sorafenib and one showed a partial response to […]

September 20, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 5 Jun 2018

French Biotech Raises €40M to Fight Hepatitis B and NASH

Enyo Pharma has completed a Series B financing round to start Phase II trials by the end of this year testing its lead compound in two different forms of liver disease. Enyo Pharma, based in Lyon, has raised €40M from OrbiMed and other investors to start two Phase II trials testing its lead drug candidate […]

June 5, 2018 - 2 minutesmins - By Alexander Burik

Alexion Pharmaceutical Wilson Therapeutics 2

News and Trends 11 Apr 2018

Alexion Acquires Swedish Treatment for Wilson’s Disease

Alexion Pharmaceutical intends to buy Wilson Therapeutics for nearly $1Bn. Wilson is developing a first-in-class treatment for Wilson’s disease, a rare disorder that can lead to severe liver and brain damage. Alexion Pharmaceuticals, one of the most successful companies in rare diseases and known for selling one of the most expensive drugs in the world, […]

April 11, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 27 Nov 2017

NASH Leader Signs Up for EU Project to Fight Deadly Liver Disease

Update 27/11/17: Genfit, the leader in the fight against NASH, has joined the LITMUS study. The company will share its experience and resources with the EU collaboration by contributing samples from its RESOLVE-IT clinical study. Genfit will co-lead two projects in patient recruitment and specialized biomarker assays, focusing on genetics and miRNA. Originally published: 23/11/17 […]

November 27, 2017 - 3 minutesmins - By Alex Dale

News and Trends 8 Nov 2017

German Pharma and Biotech Gang Up on NASH in an Exciting Collaboration

Boehringer Ingelheim’s fight against liver disease is taking shape, having agreed on a partnership with RNA pioneer MiNA Therapeutics to fight NASH. British biotech, MiNA Therapeutics, has announced a partnership with pharma giant Boehringer Ingelheim to focus on developing compounds to treat fibrotic liver diseases like Non-Alcoholic SteatoHepatitis (NASH). Bringing MiNA on board has given Boehringer Ingelheim access to […]

November 8, 2017 - 3 minutesmins - By Alex Dale

News and Trends 29 Jun 2017

This French Biotech is Starting Two New Trials to Treat Kidney and Liver Fibrosis

Genkyotex has announced a new Phase II trial in diabetic kidney disease and patient enrolment in another Phase II study for PBC. Genkyotex is not giving up after its lead candidate, GKT831, failed to meet the primary endpoint in a Phase II trial in patients with type 2 diabetes and kidney disease. The French biotech has […]

June 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Liver disease

€15M to Take Swiss Biotech’s Liver Cirrhosis Treatment to Phase II

Drug for Autoimmune Liver Disease Yields Mixed Results in Hard-to-Treat Patients

Swiss Biotech Raises €11M to Develop Treatments for Liver Fibrosis

First Stem Cell Therapy for Liver Failure Shows Promise in First Human Trials

Genfit Gets Ready to Launch Drug for Untreated Liver Disease Raising €120M

Solid Phase II Performance for French Autoimmune Liver Disease Drug

RNA Therapy Shows Promise for Treating Liver Cancer

French Biotech Raises €40M to Fight Hepatitis B and NASH

Alexion Acquires Swedish Treatment for Wilson’s Disease

NASH Leader Signs Up for EU Project to Fight Deadly Liver Disease

German Pharma and Biotech Gang Up on NASH in an Exciting Collaboration

This French Biotech is Starting Two New Trials to Treat Kidney and Liver Fibrosis

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!